0000000000082272

AUTHOR

Octavio Burgues

showing 23 related works from this author

A prognostic miRNA based signature in early-stage HER2-positive breast cancer patients.

2021

e12600 Background: In early-stage HER2+ breast cancer (BC), escalation or de-escalation of systemic treatment is an unmet need. Integration of promising biomarkers into risk scoring will further help progressing in the field. We aim to develop a prognostic signature that integrates two miRNAs (A and B) and quantitative and qualitative clinical variables in patients diagnosed with HER2+ BC. Methods: This study was conducted in a retrospective cohort of 45 HER2+ BC patients. Patients received standard treatment for localized disease. We calculated a prognostic signature for disease-free survival (DFS) using principal components analysis for mixed data combining clinicopathological data (Ki67…

OncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.diseaseUnmet needsBreast cancerOncologyHER2 Positive Breast CancerInternal medicinemicroRNAmedicineStage (cooking)businessJournal of Clinical Oncology
researchProduct

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

2019

Background Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature. Methods Epigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed. Patients included were categorized according to previous response to NAC in responder (pCR or residual cancer burden, RCB = 0) or non-responder (non-pCR or RCB > 0) patients. A methyloma study was performed in a discovery cohort by the Infinium HumanMethylation450 BeadChip (450K arra…

0301 basic medicineOncologymedicine.medical_treatmentADNlcsh:MedicineTriple Negative Breast NeoplasmsEpigenesis Genetic0302 clinical medicineGenetics (clinical)Triple-negative breast cancermedicine.diagnostic_testHigh-Throughput Nucleotide SequencingNuclear ProteinsMethylationMiddle AgedNeoadjuvant TherapyGene Expression Regulation NeoplasticTreatment OutcomeMyogenic Regulatory FactorsEfectes secundaris dels medicaments030220 oncology & carcinogenesisCohortFemaleTaxoidsMetilacióMicrotubule-Associated ProteinsAdultmedicine.medical_specialtylcsh:QH426-470MethylationMinor Histocompatibility Antigens03 medical and health sciencesBreast cancerTriple-negative breast cancerInternal medicineCell Line TumorBiopsyGeneticsmedicineHumansEpigeneticsMolecular BiologyEpigenetic signatureAgedChemotherapybusiness.industryGene Expression ProfilingResearchlcsh:RSequence Analysis DNADNADNA Methylationmedicine.diseaseHuman geneticsRepressor Proteinslcsh:Genetics030104 developmental biologyDrug side effectsbusinessPredictionDevelopmental Biology
researchProduct

Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

2018

Oncologymedicine.medical_specialtyMolecular screeningbusiness.industryAdvanced breastCancerHematologymedicine.diseaseBreast cancerOncologyInternal medicinemedicineAGATAbusinessAnnals of Oncology
researchProduct

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer

2021

Background Recently, microRNAs have been demonstrated to be potential non-invasive biomarkers for diagnosis, prognosis assessment or prediction of response to treatment in cancer. In this study, we evaluate the potential of miR-30b-5p as a biomarker for early diagnosis of breast cancer (BC) in tissue and plasma. Methods Expression of miR-30b-5p was determined in a series of 112 BC and 40 normal breast tissues. Circulating miR-30b-5p levels in plasma samples were determined in a discovery cohort of 38 BC patients and 40 healthy donors and in a validation cohort of 83 BC patients and 83 healthy volunteers. miR-30b-5p expression was measured by quantitative real-time PCR and receiver operating…

OncologyCancer Researchmedicine.medical_specialtydiagnosisBreast NeoplasmsBreast cancerbreast cancerPositive axillary lymph nodeInternal medicinemicroRNAmedicineBiomarkers TumorHumansStage (cooking)plasmaEarly Detection of CancerOriginal ResearchReceiver operating characteristicmicroRNAbusiness.industryCancermedicine.diseasePrognosisMicroRNAsOncologyCohortBiomarker (medicine)FemalebusinessESMO Open
researchProduct

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma

2016

Background: NF-κB signalling appears deregulated in breast tumours. The purpose of this study was to determine whether the non-canonical NF-κB pathway, is activated in oestrogen receptor positive (ER+) breast cancer, to identify any correlation between its activity and the clinico-pathological phenotype and to explore whether NF-κB2 and RelB subunits and/or any of their target genes might be used as a predictive marker. Methods: Two independent cohorts of ER+ early breast cancer patients treated with adjuvant endocrine therapy were included in the study. Activation of RelB and NF-κB2 subunits was determined in a training set of 121 patients by measuring DNA-binding activities in nuclear ext…

0301 basic medicineOncologyAdultCancer Researchmedicine.medical_specialtyBreast NeoplasmsER-positiveNF-κBCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerbreast cancernon-canonicalInternal medicinemedicineHumansMolecular DiagnosticsAgedAged 80 and overPredictive markerOncogenebusiness.industryRELBNF-kappa BMiddle Agedmedicine.diseasePrognosis030104 developmental biologyOncologyReceptors Estrogen030220 oncology & carcinogenesisFemaleLiver cancerBreast carcinomabusinessEstrogen receptor alphaBritish Journal of Cancer
researchProduct

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.

2012

Abstract Purpose Whether or not to biopsy the metastasis in recurrent breast cancer has become mired in controversy. Several studies have shown an important discordance of the immunohistochemical (IHC) determinations for ER, PR and HER2 between primary (PT) and recurrent tumors (RT). Yet it remains unknown within this what impact technical issues have. The aim of our study was to assess whether technical variability might have an impact on the concordance between PT and RT. Methods IHC determinations in paired biopsies from PT and RT were compared under routine vs study conditions. In the former, pathological analysis reproduced the conditions used in the routine of a University Pathology D…

OncologyAdultmedicine.medical_specialtyReceptor ErbB-2ConcordanceBone NeoplasmsBreast NeoplasmsMetastasisBreast cancerInternal medicineBiopsymedicineHumansPathologicalAgedRetrospective StudiesGynecologyAged 80 and overmedicine.diagnostic_testbusiness.industryConfoundingGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerImmunohistochemistryReceptors EstrogenImmunohistochemistrySurgeryFemalebusinessReceptors ProgesteroneBreast (Edinburgh, Scotland)
researchProduct

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

2011

Abstract The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 μm were used for DNA extraction and slides of 3 μm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a central laboratory for both primary tumors and metastases. PTEN levels were assessed by IHC and phosphoinositide 3-kinase (PI3K) pathway mutations were detected by a mass spectroscopy–based approach. Median age was 48 years (range: 30–83 years). Tumor subtype included 72% horm…

AdultCancer Researchmedicine.medical_specialtyClass I Phosphatidylinositol 3-KinasesReceptor ErbB-2Breast Neoplasmsmedicine.disease_causeArticleMetastasisMetastasisPhosphatidylinositol 3-KinasesBreast cancerInternal medicineBreast CancermedicinePTENHumansPTEN lossReceptorneoplasmsPI3K/AKT/mTOR pathwayAgedAged 80 and overMutationbiologyPTEN PhosphohydrolaseMiddle Agedmedicine.diseaseMetastatic breast cancerEndocrinologyOncologyReceptors EstrogenMutationbiology.proteinCancer researchImmunohistochemistryFemalePIK3CA mutationsReceptors ProgesteroneSignal TransductionMolecular cancer therapeutics
researchProduct

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

2014

Abstract There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary and recurrent breast cancer. Targeted next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 3,320 exons of 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer. Point mutations, indels, copy-number alterations (CNA), and select rearrangements were assessed in 74 tumors from 43 patients (36 primary and 38 recurrence/metastases). Alterations potentially targetable with established or investigational therapeutics were considered “actionable.” Alterations…

AdultCancer ResearchARID1AConcordanceBreast NeoplasmsGenomicsArticleExonBreast cancermedicineCluster AnalysisHumansPTENNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overbiologyGene Expression ProfilingPoint mutationGenomicsMiddle Agedmedicine.diseaseGene Expression Regulation NeoplasticGene expression profilingOncologyMutationbiology.proteinCancer researchFemaleNeoplasm Recurrence LocalMolecular Cancer Therapeutics
researchProduct

Cutaneous sclerosing Pacinian-like perineurioma

2001

Cutaneous sclerosing Pacinian-like perineurioma Aims: The term perineurioma has been used to designate a variety of clinically and histologically different proliferations of perineurial cells based on immunohistochemical and/or ultrastructural characterization. There are two different groups of neoplasms derived from perineurial cells: extraneural or soft tissue perineuriomas, and intraneural perineuriomas. Recently, a sclerosing variant of cutaneous perineurioma has been described. Methods and results: We report a case of a cutaneous form of perineurioma, combining features of the intraneural and sclerosing varieties, as well as showing a Pacinian pattern of growth. In order to assess the …

Pathologymedicine.medical_specialtyHistologymedicine.diagnostic_testSoft tissueGeneral MedicineAnatomyBiologyExtraneuralPerineurial CellPathology and Forensic Medicinemedicine.anatomical_structurePerineuriomamedicineImmunohistochemistryPerineuriumChromosome 22Fluorescence in situ hybridizationHistopathology
researchProduct

Incidence of oncogenes in PI3K/AKT and MAPK signaling pathways in breast cancer

2015

Breast cancerOncologybusiness.industrymedicineCancer researchHematologymedicine.diseasebusinessCarcinogenesismedicine.disease_causeProtein kinase BPI3K/AKT/mTOR pathwayMapk signaling pathwayAnnals of Oncology
researchProduct

Abstract PD3-6: ConvertHER: Evolution of genomic alterations from primary to metastatic breast cancer

2015

Abstract Background: Changes in breast cancer receptor status over disease progression and treatment have been described to a point that could alter response to therapy. There is growing interest in delivering biomarker/genomically-based targeted therapies. We aimed to determine the concordance of genomic alterations between primary (P) and metastatic (M) breast cancer in a prospective collection study. Methods: Targeted capture and next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 202 cancer relevant genes in 61 pairs (primary and corresponding recurrence/metastasis). Tumors were classified at baseline as [hormone receptor (HR)+/HER2-, H…

OncologyCancer Researchmedicine.medical_specialtyPathologybusiness.industryMAP3K1medicine.diseaseMetastatic breast cancerMetastasisExonBreast cancerOncologyInternal medicinemedicineMEN1skin and connective tissue diseasesbusinessExome sequencingTriple-negative breast cancerCancer Research
researchProduct

The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach

2019

Abstract Background Breast cancer (BC) is a heterogeneous disease. HER2+ BC represents between 15-30% of cases. Trastuzumab (T), a monoclonal antibody, has been successfully improved clinical benefits in both adjuvant and in metastatic settings. Despite this evidence, many patients experience resistance to therapy. The objective of this study is to assess AXL as a potential mechanism of resistance and its implication as a prognostic factor. Methods We used three cell lines with acquired resistance to T. Resistant models were generated by treating parental cells (AU565, SKR3, BT474) with constant dose of T (15mg/mL) for 6 months. Cell viability was estimated by MTT assay. Proteins were asses…

Oncologymedicine.medical_specialtyCombination therapymedicine.diagnostic_testbusiness.industrymedicine.drug_classmedicine.medical_treatmentHematologyMonoclonal antibodymedicine.diseasePrimary tumorFlow cytometryBreast cancerOncologyTrastuzumabInternal medicinemedicineEpithelial–mesenchymal transitionbusinessAdjuvantmedicine.drugAnnals of Oncology
researchProduct

No effect of length time bias on the genomic risk in ER+ HER2-stage I-IIA breast cancer (BC) patients according to diagnosis in a screening programme…

2018

Screening programmeOncologymedicine.medical_specialtyBreast cancerOncologybusiness.industryInternal medicineMedicineHematologyExploratory analysisLength time biasbusinessmedicine.diseaseAnnals of Oncology
researchProduct

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.

2021

558 Background: Genomic platforms, such as Mammaprint (Agendia) (MP) and OncoType (Genomic Health) (OT), have been validated to determine the risk of relapse in therapeutic decision-making in early-stage hormone receptor positive (HR+), epidermal growth factor receptor 2 (HER2) negative breast cancer (BC). Discordances in risk allocation between these platforms affect up to 30% of patients. This study aims to develop the MamaPred test to improve the diagnostic performance of recurrence risk in HR+/HER2- early-stage BC. Methods: A total of 606 HR+/HER2- early-stage BC previously tested with OT [n = 287; Low Risk (LR) = 165, Intermediate Risk (IR) = 103 and High Risk (HR) = 19] and MP (n = 3…

OncologyCancer Researchmedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.diseaseRecurrence riskBreast cancerOncologyMammaPrintInternal medicinemedicineRelapse riskStage (cooking)businessJournal of Clinical Oncology
researchProduct

Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?

2010

Resection of intact primary tumor is controversial in metastatic breast cancer patients. The aim of this study is to review the impact of surgical resection of primary tumor on overall survival and to assess the role of timing of surgery on survival rates.208 patients with metastatic breast cancer diagnosed between 1982 and 2005 in the Hospital Clinico of Valencia (Spain) were analysed. Exclusion criteria were age80, PS 3-4, Charlson score 3 or follow-up90 days. 123 of these underwent surgery and 85 did not. In order to assess the role of timing, the "surgery" cohort was divided into two sub-groups: "before" (n = 78) or "after" (n = 45) diagnosis of disseminated disease.In the surgery group…

medicine.medical_specialtyTime FactorsBreast surgerymedicine.medical_treatmentBreast NeoplasmsmedicineHumansNeoplasm MetastasisMastectomySurvival analysisNeoplasm StagingRetrospective StudiesUnivariate analysisPerformance statusbusiness.industryCarcinoma Ductal BreastGeneral MedicineMiddle Agedmedicine.diseaseDebulkingSurvival AnalysisPrimary tumorMetastatic breast cancerSurgeryCarcinoma LobularTreatment OutcomeSpainFemaleSurgerybusinessMastectomyThe Breast
researchProduct

miR-503-5p induces doxorubicin resistance in triple-negative breast cancer.

2021

1083 Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer (BC) subtype comprising approximately 15% of BC. Conventional cytotoxic chemotherapies continue to be the mainstay for treatment of this BC, which lacks targetable markers. In this context, microRNAs have been described to have an important role. The aim of this work was to elucidate the function of miR-503-5p in doxorubicin resistance in TNBC. Methods: miR-503-5p expression was evaluated in the TNBC cell line with acquired resistance to doxorubicin (MDA-MB-231R) and its parental cell line (MDA-MB-231), by qRT-PCR. Studies of gain/loss of function of miR-503-5p were carried out in MDA-MB-231 and MDA-MB-231…

Cancer ResearchBreast cancerOncologybusiness.industryCancer researchmedicineCytotoxic T cellDOXORUBICIN RESISTANCEmedicine.diseasebusinessTriple-negative breast cancerJournal of Clinical Oncology
researchProduct

Global transcriptome deregulation of breast cancer in very young women samples

2017

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryHematologymedicine.diseaseTranscriptome03 medical and health sciencesDeregulation030104 developmental biologyBreast cancerOncologyInternal medicinemedicinebusinessAnnals of Oncology
researchProduct

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver

2019

AbstractAs the catalogue of oncogenic driver mutations is expanding, it is becoming clear that alterations in a given gene should not be lumped into one single class, since they might have different functions. The transcription factorGATA3is a paradigm of this. Here, we address the functions of the most commonGATA3mutation (X308_Splice) which generates a neoprotein that we designate as neoGATA3, associated with good patient prognosis. Based on extensive analyses of molecular and clinical data from approximately 3000 breast cancer patients, supported by mechanistic studiesin vitro, we show that neoGATA3 interferes with the transcriptional programs controlled by estrogen and progesterone rece…

0303 health sciencesGATA3CancerContext (language use)Biologymedicine.disease03 medical and health sciences0302 clinical medicineBreast cancer030220 oncology & carcinogenesisMutation (genetic algorithm)Cancer researchmedicinespliceTranscription factorGene030304 developmental biology
researchProduct

Thirteen miRNAs involved in the response of breast cancer cells to doxorubicin.

2013

e12019 Background: Mature microRNAs (miRNAs) are a class of naturally occurring, small non-coding RNA molecules, about 21–25 nucleotides. Growing evidence shows that miRNAs exhibit a variety of regulatory functions related to cell growth, development, and differentiation, and are associated with a wide variety of human diseases. Several miRNAs have been linked to cancer; since expression analysis studies have revealed perturbed miRNA expression in tumors compared to normal tissues. As a consequence, human miRNAs are likely to be highly useful as biomarkers, especially for future cancer diagnostics, and are emerging as targets for disease intervention. Since doxorubicin (DOX) has been used …

Cancer ResearchCell growthRNACancerDiseaseBiologymedicine.diseaseBioinformaticsBreast cancerOncologymicroRNAmedicineDoxorubicinBreast cancer cellsmedicine.drugJournal of Clinical Oncology
researchProduct

Overexpression of the truncated form of high mobility group a proteins (HMGA2) in human myometrial cells induces leiomyoma-like tissue formation

2014

The pathogenesis of uterine leiomyomas, the most common benign tumor in women, is still unknown. This lack of basic knowledge limits the development of novel non-invasive therapies. Our group has previously demonstrated that leiomyoma side population (SP) cells are present in tumor lesions and act like putative tumor-initiating stemcells in human leiomyoma. Moreover, accumulated evidence demonstrates that these benign tumors of mesenchymal origin are characterized by rearrangements of the High Mobility Group A proteins (HMGA). In this work, we tested the hypothesis that leiomyoma development may be due to overexpression of HMGA2 (encoding high mobility group AT-hook2) in myometrial stem cel…

EmbryologyMice SCID//purl.org/becyt/ford/1 [https]MiceMice Inbred NODProtein IsoformsUterine leiomyomaLeiomyomaStem CellsSOMATIC STEM CELLSObstetrics and GynecologyExonsBioquímica y Biología Molecularfemale genital diseases and pregnancy complicationsGene Expression Regulation NeoplasticCell Transformation NeoplasticLeiomyomaUterine NeoplasmsMyometriumNeoplastic Stem CellsFemaleStem cellHIGH MOBILITY GROUP A PROTEINSCIENCIAS NATURALES Y EXACTASPlasmidsAdult stem cellmedicine.medical_specialtyUTERINE LEIOMYOMASMyocytes Smooth MuscleTransplantation HeterologousBiologyTransfectionHUMAN MYOMETRIUMCiencias BiológicasHMGA2Side populationInternal medicineGeneticsmedicineAnimalsHumans//purl.org/becyt/ford/1.6 [https]neoplasmsMolecular BiologyHMGA2 ProteinMesenchymal stem cellHMGASIDE POPULATIONCell Biologymedicine.diseaseIntronsEndocrinologyReproductive MedicineCancer researchbiology.proteinDevelopmental Biology
researchProduct

Biphasic dermatofibrosarcoma protuberans with a labyrinthine plexiform high‐grade fibrosarcomatous transformation

2013

Several variants of dermatofibrosarcoma protuberans, a low-grade superficial sarcoma, are well recognized. The most prognostically important is the fibrosarcomatous variant. We report a case of biphasic dermatofibrosarcoma protuberans in which the high-grade component exhibited a previously undescribed plexiform pattern. A clinicopathological study complemented with immunohistochemical, ultrastructural, reverse transcription polymerase chain reaction and fluorescence in situ hybridization analyses of this unique case. Histopathologically, a conventional low-grade dermatofibrosarcoma protuberans was admixed with intratumoral high-grade areas showing a striking labyrinthine plexiform pattern …

MalePathologymedicine.medical_specialtySkin NeoplasmsHistologyOncogene Proteins FusionFibrosarcomaCD34DermatologyBiologyPathology and Forensic MedicinemedicineDermatofibrosarcoma protuberansHumansIn Situ Hybridization FluorescencePDGFBmedicine.diagnostic_testDermatofibrosarcomaMiddle AgedPrognosismedicine.diseaseImmunohistochemistryCell Transformation NeoplasticCOL1A1/PDGFB Fusion GeneImmunohistochemistrySarcomaImmunostainingFluorescence in situ hybridizationJournal of Cutaneous Pathology
researchProduct

Patología de los tumores neuroblásticos: evaluación pronóstica. Experiencia del centro español de referencia de la SEOP para estudios biopatológicos …

2007

Resumen Antecedentes Los tumores neuroblasticos son los tumores solidos extracraneales mas frecuentes en la infancia y se caracterizan por una evolucion clinica heterogenea que va desde una progresion rapida a una regresion tumoral espontanea. Existen factores pronosticos conocidos que determinan dicha evolucion como son la edad, estadiaje, histopatologia, estatus de MYCN, ploidia y diversas ganancias y perdidas cromosomicas. El objetivo del trabajo es describir nuestra experiencia como laboratorio de referencia espanol para la determinacion de estos parametros pronosticos. Metodos Material tumoral de pacientes con neuroblastoma, remitido a nuestro laboratorio desde 1992 hasta 2005, ha sido…

business.industryMedicinebusinessHumanitiesPathology and Forensic MedicineRevista Española de Patología
researchProduct

Clinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine

2019

Abstract Background The identification of biomarkers to drive treatment is one of the most important objectives of precision medicine. During last years, the role of PIK3CA mutations have been related to clinical benefit deriving from treatment with PI3K, and mTOR inhibitors. In breast cancer (BC), PIK3CA mutations are widely present and the use, in clinical trials, of selective inhibitors improved clinical outcomes. The aim of this study is to assess the value of a monocentric genomic screening program to select patients for trials with experimental targeted agents. Methods We examined PIK3CA mutation in a cohort of 312 metastatic BC patients diagnosed at Hospital Clinico Valencia-INCLIVA …

0301 basic medicinemedicine.medical_specialtybusiness.industryHematologymedicine.diseaseDiscovery and development of mTOR inhibitorsPrecision medicineGenomic screeningClinical trialMutational analysis03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicineCohortmedicinebusinessTriple negativeAnnals of Oncology
researchProduct